The Food and Drug Administration (FDA) has expanded the approval of Baqsimi (glucagon) nasal powder to include the treatment of severe hypoglycemia in patients aged 1 year and older with diabetes.

Hypoglycemia refers to low blood sugar (glucose) levels. When sugar levels fall too low, a person may be at risk of severe complications, such as losing consciousness or having a seizure.

The bills, which have advanced in the Senate, would require schools to take certain preventative measures to protect student ...

Clinical hold lifted for late stage cadisegliatin program for diabetes CATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to resume Q2 2025 Strengthens commercial leadership with appo ...

Explore Xeris Biopharma's revenue growth, promising pipeline, & thriving products. Learn about their strong outlook & ...

PNC Financial Services Group Inc. lifted its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Free Report ...

In the latter clinical contexts, ipratropium bromide nasal therapy can be considered ... calcium-channel blockers for essential hypertension, glucagon-like peptide 1 receptor agonists for diabetes ...

AlphaQuest LLC reduced its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Free Report) by 35.9% in the ...